Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
The McCaw Endowed Chair of Muscular Dystrophy at University of Washington discussed the role the ASGCT plays in the field.
“An important role for the American Society for Gene and Cell Therapy to play is to be an advocate for different areas, and regulation is one of those [areas]. We've, for many years had a very close and good relationship with the FDA... ASGCT plays, I think, an important role in bringing people together with the FDA, educating our community about what needs to be done, what's out there, and in and the FDA is now in a position, I think they're going to be approving a lot more therapies, there's so many things in the pipeline, they're getting close to approval, I think the next year or two are just going to be fantastic.
The American Society of Gene and Cell Therapy (ASGCT) held its 27th Annual Meeting on May 7-11, in Baltimore, Maryland. The meeting, the society’s biggest to date, brought together over 8000 researchers, clinicians, academic centers, regulatory agencies, and industry involved in gene and cell therapy work to share their work and generate collaborative discussions in the field.
CGTLive® spoke with Jeffrey Chamberlain, PhD, Professor, Neurology and Medical Genetics, and Adjunct Professor, Biochemistry, and McCaw Endowed Chair, Muscular Dystrophy, University of Washington, who served as ASGCT’s president for 2023-2024, to learn more about ongoing and future research in the fields of cell and gene therapy, Chamberlain stressed that cost is a huge issue to tackle in the field and will hopefully trend downward as economies of scale come into place. He also noted that the ASGCT plays an important role in bringing together regulators with key players in the field.
Sequencing of Treatment in Third-Line R/R LBCL
January 15th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.
Confirming the Safety of Pfizer's Hemophilia B Gene Therapy Beqvez
December 22nd 2024Ben Samelson-Jones, MD, PhD, the associate director of clinical in vivo gene therapy at Children’s Hospital of Philadelphia, discussed follow-up data of up to 6 years with investigations of fidanacogene elaparvovec.
